(Q35053466)

6 August 2017

1 reference

title

Effects of HIV protease inhibitor therapy on lipid metabolism (English)

1 reference

6 August 2017

David Y Hui

1

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Progress in Lipid Research

6 August 2017

published in

1 reference

6 August 2017

volume

42

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

81-92

1 reference

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Hyperlipidemia associated with protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Vascular and lipid syndromes in selected HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Vascular complications associated with use of HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Vascular complications associated with use of HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Severe premature coronary artery disease with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Metabolic effects of indinavir in healthy HIV-seronegative men

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Protease inhibitor-associated hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

New-onset diabetes mellitus associated with use of protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Identification of complexes between the COOH-terminal domains of sterol regulatory element-binding proteins (SREBPs) and SREBP cleavage-activating protein

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Cleavage site for sterol-regulated protease localized to a leu-Ser bond in the lumenal loop of sterol regulatory element-binding protein-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Structure of 20S proteasome from yeast at 2.4 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Structural investigation of proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

1 reference

7 January 2021

Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Transcriptional activation of the stearoyl-CoA desaturase 2 gene by sterol regulatory element-binding protein/adipocyte determination and differentiation factor 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Identification of glycerol-3-phosphate acyltransferase as an adipocyte determination and differentiation factor 1- and sterol regulatory element-binding protein-responsive gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Protease inhibitors and adipocyte differentiation in cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Leptin-replacement therapy for lipodystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Postprandial lipid metabolism: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Detection and characterization of the heterozygote state for lipoprotein lipase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Familial combined hyperlipidaemia linked to the apolipoprotein AI–CIII–AIV gene cluster on chromosome 11q23q–q24

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Interrelationship of triglycerides with lipoproteins and high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

The assembly and secretion of apolipoprotein B-containing lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Ubiquitin-proteasome pathway mediates intracellular degradation of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Regulated Co-translational ubiquitination of apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory protein

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Intracellular assembly and degradation of apolipoprotein B-100-containing lipoproteins in digitonin-permeabilized HEP G2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

The concept of selective leptin resistance: evidence from agouti yellow obese mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7827%2802%2900046-2

7 January 2021

10.1016/S0163-7827(02)00046-2

Identifiers

DOI

1 reference

6 August 2017

1 reference